πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,263 results for β€œCancer” Clear

  1. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Metastatic Head and Neck Cancer

    phase 3 small molecule terminated

    1 trial

  2. CALCIUM FOLINATE, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BEVACIZUMAB, BEVACIZUMAB, PANITUMUMAB, SOTORASIB, FLUOROURACIL

    Amgen Technology (Ireland) UC

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  3. CANAKINUMAB, PEMETREXED

    Novartis Ophthalmics Europe

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. CAPECITABINE , METFORMIN , ACETYLSALICYLIC ACID , OXALIPLATIN

    Fondazione Telethon ETS

    Locally advanced stage II/III rectal cancer

    phase 3 small molecule active

    1 trial

  5. CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    AstraZeneca AB

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  6. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  7. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

  8. CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB

    Daiichi Sankyo Europe GmbH

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN

    Daiichi Sankyo Europe GmbH

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED

    AstraZeneca AB

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial

  12. CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  14. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Roche Registration Limited

    RET fusionβˆ’positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. CARBOPLATIN, PACLITAXEL, DOCETAXEL, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  16. CISPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  17. CISPLATIN , PACLITAXEL , GEMCITABINE , CARBOPLATIN , placebo for mRNA-4157, PEMETREXED , mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  19. CISPLATIN, CARBOPLATIN

    Cardiff Oncology

    Human papillomavirus (HPV)-positive oropharyngeal cancer

    phase 3 small molecule active

    1 trial

  20. CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  21. CISPLATIN, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, PEMETREXED, CARBOPLATIN, CISPLATIN, AMIVANTAMAB, AMIVANTAMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, OSIMERTINIB, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Advanced HER2-expressing Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  23. CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    First-line patients with advanced biliary tract cancers (BTC)

    phase 3 small molecule active

    1 trial

  24. CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED

    AstraZeneca AB

    Non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources